[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467608":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":36,"responsibleParty":53,"collaborators":56,"id":60,"slug":21,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":21,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":21,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":21,"overallStatus":39,"whyStopped":21,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"The University of Texas Health Science Center, Houston","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Fear Conditioning and Extinction Paradigm, plus Transcranial Magnetic Stimulation (TMS)","EXPERIMENTAL","Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day.\n\nOn day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner.\n\nOn day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day.",[13,14],"Device: Transcranial magnetic stimulation (TMS)","Behavioral: Fear Conditioning and Extinction Paradigm",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DEVICE","Transcranial magnetic stimulation (TMS)","Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.",[9],null,{"type":23,"name":24,"description":11,"armGroupLabels":25,"otherNames":21},"BEHAVIORAL","Fear Conditioning and Extinction Paradigm",[9],[27],{"name":28,"affiliation":29,"role":30},"Mohammed Milad, PhD","The University of Texas Health Science Center at Houston (UTHealth Houston)","PRINCIPAL_INVESTIGATOR",[32],{"name":28,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","713-486-2754","Mohammed.R.Milad@uth.tmc.edu",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"UTHealth Houston","RECRUITING","Houston","Texas","77054","United States",{"type":45,"coordinates":46},"Point",[47,48],-95.36327,29.76328,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":21,"phoneExt":21,"email":35},"Mohammed R. Milad, MD",{"type":30,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Mohammed Milad","Professor",[57],{"name":58,"class":59},"National Institute of Mental Health (NIMH)","NIH","100467608",false,"NCT05368987","Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans","Inclusion Criteria:\n\n* Willing and able to provide informed consent.\n* Inclusion Criteria for PTSD Subjects - Diagnosis of current PTSD\n* Inclusion Criteria: Healthy Controls (HC) - no current psychiatric disorders (\"Axis I\" disorders)\n\nExclusion Criteria:\n\n* Lifetime history of seizure or significant head trauma or other significant neurologic disease (e.g., tic disorder)\n* History of serious\u002Fsignificant psychiatric diagnoses (\"Axis I\" diagnoses)\n* Current significant suicidal ideation, plan or intent or suicidal behavior in past 6 months based on CSSRS and clinical judgment or Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily\n* Use of neuroleptics within one year prior to study\n* Current substance use\n* Pregnancy (to be ruled out by urine β-HCG).\n* Metallic implants or devices contraindicating magnetic resonance imaging.\n* Currently taking medications that lower the seizure threshold. These include antipsychotics, high dose theophylline or stimulants such as methylphenidate. Patients taking bupropion must be on a stable dose (\\*last 3 months) and take less than or equal to 300 mg\u002Fday.\n* Implanted devices in subject's head (shunts, cochlear implants); metal in subject's head (other than dental implants).\n* High risk of adverse emotional or behavioral reaction, and\u002For an inability to understand study procedures or the informed consent process\n* Additional exclusion criteria for Healthy controls (HC) group: Current psychiatric diagnosis (\"Axis I\" diagnosis)",true,"ALL","18 Years","70 Years",{"count":70,"type":71},250,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS) impacts fear circuits. The overarching objectives are to understand how varying TMS parameters affect targeted brain regions in order to optimize its impact on enhancing fear extinction memory consolidation in a population with known fear extinction deficiencies: post-traumatic stress disorder (PTSD). 250 subjects will take part in this research study across UTHealth Houston. The study will include preliminary screenings, baseline visits, and experimental visits across four days",[77],"PTSD","2026-04-30",{"date":80,"type":81},"2026-05-05","ACTUAL",{"date":83,"type":81},"2022-02-01",{"date":85,"type":71},"2028-09-30",{"name":5,"class":6},1]